The US Food and Drug Administration is reviewing Perrigo’s birth control pill for over-the-counter use in November

The U.S. Food and Drug Administration (FDA) company logo is displayed November 4, 2009 in Silver Spring, Maryland. REUTERS/Jason Reed

Sign up now for FREE unlimited access to Reuters.com

SEPTEMBER 12 (Reuters) – Perrigo Co Plc (PRGO.N) said on Monday that the US Food and Drug Administration has called a meeting of outside experts for November 18 to review the use of its daily birth control pill for over-the-counter – Use counters (OTC).

The drugmaker’s unit, HRA Pharma, filed an application with health authorities in July to manufacture its prescription contraceptive Opill, an over-the-counter pill. Continue reading

Since the June decision by the US Supreme Court to dismiss Roe v. Wade’s 1973 law that legalized abortion nationwide puts access to contraception in the spotlight. Continue reading

Sign up now for FREE unlimited access to Reuters.com

Abortion rights activists have stepped up calls for mifepristone, which when combined with misoprostol induces an abortion up to 10 weeks into a pregnancy, to be made available without a prescription. Continue reading

Opill, a non-estrogen contraceptive, has been used by prescription since it was approved in 1973. If the FDA approves HRA Pharma’s application, Opill would become the first OTC, daily-use birth control pill in the United States.

The HRA said in July it expects a decision from the FDA in the first half of 2023.

Sign up now for FREE unlimited access to Reuters.com

Reporting by Bhanvi Satija in Bengaluru; Edited by Anil D’Silva

Our standards: The Thomson Reuters Trust Principles.

Comments are closed.